SCHEMBL244618

SCHEMBL244618

Nc1cc(-c2ccc(F)cc2)n[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.54
CA12 O43570 1/20 0.54
RPA1 P27694 1/20 0.54
CRHBP P24387 1/20 0.51
MAPK1 P28482 1/20 0.51
ATM Q13315 1/20 0.51
CRHR2 Q13324 1/20 0.51
MAPT P10636 5/20 0.49
MEN1 O00255 3/20 0.49
NPC1 O15118 3/20 0.49
KMT2A Q03164 3/20 0.49
MKNK1 Q9BUB5 2/20 0.49
MKNK2 Q9HBH9 2/20 0.49
RAB9A P51151 3/20 0.46
ALOX15 P16050 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 1/20 0.44
ALOX5 P09917 1/20 0.44
RET P07949 1/20 0.43
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28466328 0.83 ALPL (0.58) ALPLCA12MAPK1MAPTMEN1
Hydrochloric Acid SCHEMBL9124767 0.82 ALPL (0.56) ALPLCA12MAPK1MAPTMEN1
SCHEMBL15656631 0.81 NOTUM (0.44) ALPLCA12RPA1MAPTNPC1
SCHEMBL474802 0.80 ALPL (0.54) ALPLCA12MAPK1MAPTMEN1
SCHEMBL1143098 0.80 SMN1; SMN2 (0.61) ALPLMAPK1MAPTMEN1NPC1
SCHEMBL1143959 0.80 ALPL (0.54) ALPLMAPTMEN1NPC1KMT2A
SCHEMBL18966078 0.80 METAP2 (0.46) ALPLCA12MAPK1MAPTNPC1
SCHEMBL168536 0.79 MAPT (0.54) MAPK1MAPTMEN1NPC1KMT2A
SCHEMBL14910868 0.79 KIF11 (0.47) ALPLCRHBPMAPK1ATMCRHR2
SCHEMBL168659 0.79 POLB (0.61) ALPLMKNK1MKNK2RAB9AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109137121-A A kind of production method of the antistatic air duct fabric of mine Er ions 宁波高新区诠宝绶新材料科技有限公司 2019-01-04 CN claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
CN-122010947-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2026-05-12 CN disclosed
CN-117126578-B Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof 中国科学院海洋研究所 2025-04-22 CN disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
CN-117126578-A Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof 中国科学院海洋研究所 2023-11-28 CN disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115996929-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2023-04-21 CN disclosed
WO-2008087529-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS SIENA BIOTECH S.P.A. (IT) 2008-07-24 WO disclosed
WO-2008067257-A2 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-06-05 WO disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
WO-2007098826-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF SIENA BIOTECH S.P.A. (IT) 2007-09-07 WO disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 ALPL 906/4885CA12 1677/4885RPA1 3476/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R ALPL 3549/4885CA12 3146/4885RPA1 4798/4885
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 ALPL 4755/4885CA12 3881/4885RPA1 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.